Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Amyloidosis Treatment Market Size & Trends

The global amyloidosis treatment market size was valued at USD 5.39 billion in 2023 and is projected to grow at a CAGR of 7.4% from 2024 to 2030. The market growth can be attributed to the rising incidence of amyloidosis among the geriatric population. Amyloidosis is a rare disease characterized by the abnormal buildup of amyloid proteins in organs and tissues, leading to organ dysfunction and severe health complications. These disorders occur in various anatomical regions such as the heart, kidneys, soft tissue, liver, and gastrointestinal tract.

The market growth was propelled by the increased number of patients with genetic mutations in blood cell DNA and underlying plasma cell disorders such as monoclonal gammopathy and myeloma. This led to the increased adoption of amyloid stabilizers to stabilize the amyloid protein and prevent its accumulation in tissues and organs, further aiding market growth. Moreover, increased demand for treatments such as chemotherapy, transplantation, and other treatments has driven the market.

Early and accurate diagnosis of amyloidosis is essential for effective treatment. Recent advancements in diagnostic technologies, such as imaging techniques and biomarker identification, have significantly improved the detection and diagnosis of amyloidosis. These advancements enable healthcare providers to identify the disease earlier, leading to better patient outcomes and increased demand for diagnostic services. For instance, the introduction of monoclonal antibodies and small molecule inhibitors has revolutionized the treatment landscape for amyloidosis, providing patients with more effective and personalized treatment options.

Moreover, heavy investments made by government initiatives for research and development activities have fueled the market growth. This surge in R&D investment is driven by the growing recognition of the unmet medical needs in the amyloidosis market and the potential for significant market opportunities. Companies have increasingly focused on developing drugs and treatments that effectively prevent the buildup with reduced side effects. In addition, growth in healthcare infrastructure and increased disposable income have encouraged patients to seek technologically advanced drugs and treatments to cure amyloidosis.

Treatment Insights

The chemotherapy segment dominated the market in 2023 with a share of 26.5% owing to its effectiveness in managing amyloidosis, particularly AL amyloidosis. Chemotherapy targets and destroys the abnormal plasma cells that produce amyloid proteins, thereby reducing the production of these harmful proteins and alleviating symptoms. Recent developments in chemotherapy have led to the introduction of more effective and less toxic drugs, improving patient outcomes and reducing side effects, making chemotherapy a viable option for treating amyloidosis. In addition, chemotherapy and supportive care aid in enhancing survival rates and quality of life of the patients.

The transplantation segment is expected to emerge at the fastest-growing CAGR over the forecast period. Patients with advanced disease stages have increasingly preferred transplantation for their effectiveness in managing amyloidosis. Transplantation, such as autologous stem cell transplantation (ASCT), can significantly improve patient outcomes by replacing damaged cells with healthy ones. Moreover, the growing healthcare sector has resulted in the increased availability of transplant facilities, making the treatment more accessible to patients. Furthermore, increased awareness regarding the diagnosis of amyloidosis symptoms and their treatment has encouraged timely intervention with transplantation, propelling the segment growth.

End-use Insights

Hospitals and clinics have secured the dominant market share of 49.3% in 2023 owing to the rising incidence of amyloidosis, among the aging population that prefer specialized healthcare services. Amyloidosis often requires a comprehensive treatment approach involving various medical specialties, including cardiology, nephrology, and hematology. Hospitals and clinics are well-equipped to provide this multidisciplinary care, offering patients a coordinated and holistic treatment plan. Innovations such as advanced imaging techniques, biomarker identification, and novel therapeutic agents have enhanced the ability of healthcare providers to diagnose and treat amyloidosis more accurately.

The home care settings segment is projected to grow at a CAGR of 8.6% during the forecast period attributed to the increased preference of home care settings by patients due to personalized care and cost-effectiveness. Patients with amyloidosis often require long-term management and frequent monitoring, which can be more comfortably and conveniently provided in a home care setting. Companies have introduced several equipment such as telemedicine, remote monitoring devices, and portable diagnostic tools to cater to the rising demand of home-based care.

Regional Insights

The North America amyloidosis treatment market marked a lucrative share of 39.4% in 2023 pertaining to the presence of a well-established healthcare infrastructure and growing awareness regarding amyloidosis diseases. Major companies have targeted to increase the availability of improved and technologically advanced drugs and treatment options to the patients.

U.S. Amyloidosis Treatment Market Trends

The amyloidosis treatment in the U.S. was driven by the increased prevalence of amyloidosis diseases. Major research institutes have invested heavily in research and development efforts to manufacture better drugs and treatments to treat amyloidosis diseases. Furthermore, the increased disposable income coupled with favorable health insurance facilities in the country has contributed to market growth.

Europe Amyloidosis Treatment Market Trends

The Europe amyloidosis treatment marketheld a significant market share in 2023 attributable to the country’s massive development in the healthcare sector. The market was also driven by a rise in the demand for amyloidosis treatments due to increased awareness spread by the government and non-government organizations. Major companies in the region have targeted manufacturing effective and accurate drugs and treatment in order to mitigate the demand for effective treatments with minimal side effects.

Asia Pacific Amyloidosis Treatment Market Trends

The Asia Pacific amyloidosis market is expected to witness a CAGR of 8.1% over the forecast period owing to the increased awareness among the growing geriatric population. Increased awareness campaigns and investments made by governments to advance the healthcare sector in the region have encouraged patients to seek diagnosis and treatment of their diseases.

Key Amyloidosis Treatment Company Insights

The amyloidosis market is intensely competitive, featuring some of the major players including Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, and more. These companies have increasingly focused on improving the efficiency and accuracy of the amyloidosis treatment with technological advancements, drug development, and strategic collaborations.

• Pfizer Inc. is a biotechnology and pharmaceutical company that specializes in development and sale of medicines and vaccines for oncology, immunology, endocrinology, neurology, and more.

• Johnson & Johnson Services, Inc. is a biotechnology, pharmaceutical, and medical technologies company, which specializes in the production and sale of pharmaceutical drugs and medical device technologies.

Recent Developments

• In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of results from APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis. The study reported that the patisiran preserved functionality capacity, health status, and quality of life compared with placebo at 12 months.

Amyloidosis Treatment Market Report Scope

Global Amyloidosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global amyloidosis treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Immunosuppressive Drugs

  • Transplantation

  • Supportive Care

  • Surgery

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Home Care Settings

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait